Religare Enterprises released its FY26 annual report, highlighting a PAT of Rs 7,316.38 crore and a successful Rs 1,500 crore capital raise. While the RBI lifted the Corrective Action Plan on its lending arm, Religare Finvest, the regulator has denied the company's proposed demerger scheme. Shareholders face mixed signals as the firm balances strengthened capital adequacy with significant structural uncertainty regarding its future roadmap.
Religare Enterprises: FY26 Performance and Structural Challenges
Profit After Tax (PAT) for FY 2025-26 stood at Rs 7,316.38 crore, down from Rs 18,275.22 crore in the previous fiscal. Total income for the year grew to Rs 8,493.84 crore, compared to Rs 7,405.47 crore in FY 2024-25.
Reader Takeaway: Improved operational health via capital raise, yet face significant uncertainty following the RBI's rejection of the demerger.
What just happened
Religare Enterprises released its annual report for FY26 and confirmed that the RBI has declined its application for the demerger of its financial services business into Religare Finvest Limited (RFL). Concurrently, the company successfully completed a preferential issue of Rs 1,500 crore in convertible warrants to boost growth capital. The board also re-designated Mr. Arjun Lamba as the Managing Director, effective August 12, 2026.
Why this matters
The rejection of the demerger plan is a major blow to the company's long-term restructuring strategy. Investors who were looking for a streamlined corporate structure to unlock value in the financial services and health insurance verticals must now recalibrate expectations as management enters further dialogue with the regulator.
The backstory
Religare Finvest had been operating under an RBI-imposed Corrective Action Plan (CAP) due to historical regulatory concerns. In a significant positive shift, the RBI removed this CAP effective July 23, 2025, allowing for a business revival. Despite this relief, the broader group continues to navigate ongoing legal and regulatory scrutiny involving entities like the SFIO and NCLT.
Risks to watch
The primary risk remains the regulatory stalemate regarding the group's structural roadmap. Any further delays or negative developments in the engagement with the RBI regarding the demerger could impact investor sentiment. Ongoing legal proceedings remain a recurring overhang on the stock.
What to track next
Shareholders should monitor the outcomes of the 42nd Annual General Meeting scheduled for September 24, 2026. Additionally, watch for any formal updates or revisions to the corporate restructuring strategy following management's continued discussions with the central bank.